% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{vanTilburg:170170,
author = {C. M. van Tilburg and E. Pfaff and K. W. Pajtler$^*$ and K.
P. S. Langenberg and P. Fiesel and B. C. Jones and G. P.
Balasubramanian and S. Stark and P. D. Johann and M.
Blattner-Johnson and K. Schramm and N. Dikow and S. Hirsch
and C. Sutter and K. Grund and A. von Stackelberg and A. E.
Kulozik and A. Lissat and A. Borkhardt and R. Meisel and D.
Reinhardt and J.-H. Klusmann and G. Fleischhack and S.
Tippelt and D. von Schweinitz and I. Schmid and C. M. Kramm
and A. O. von Bueren and G. Calaminus and P. Vorwerk and N.
Graf and F. Westermann and M. Fischer and A. Eggert and B.
Burkhardt and W. Wossmann and M. Nathrath and S.
Hecker-Nolting and M. C. Fruhwald and D. T. Schneider and I.
B. Brecht and P. Ketteler and S. Fulda and E. Koscielniak
and M. T. Meister and M. Scheer and S. Hettmer and M. Schwab
and R. Tremmel and I. Ora and C. Hutter and N. U. Gerber and
O. Lohi and B. Kazanowska and A. Kattamis and M. Filippidou
and B. Goemans and C. M. Zwaan and T. Milde and N. Jäger
and S. Wolf$^*$ and D. Reuss$^*$ and F. Sahm$^*$ and A. von
Deimling$^*$ and U. Dirksen and A. Freitag and R. Witt and
P. Lichter$^*$ and A. Kopp-Schneider$^*$ and D. T. W.
Jones$^*$ and J. J. Molenaar and D. Capper and S. Pfister
and O. Witt$^*$},
title = {{T}he pediatric precision oncology {INFORM} registry:
clinical outcome and benefit for patients with very
high-evidence targets.},
journal = {Cancer discovery},
volume = {11},
number = {11},
issn = {2159-8290},
address = {Philadelphia, Pa.},
reportid = {DKFZ-2021-01794},
pages = {2764-2779},
year = {2021},
note = {#LA:B310# / 2021 Nov;11(11):2764-2779},
abstract = {INFORM is a prospective, multi-national registry gathering
clinical and molecular data of relapsed, progressive or
high-risk pediatric cancer patients. This report describes
long-term follow-up of 519 patients in whom molecular
alterations were evaluated according to a pre-defined
7-scale target prioritization algorithm. Mean turnaround
time from sample receipt to report was 25.4 days. The
highest target priority level was observed in 42 patients
$(8.1\%).$ Of these, twenty patients received matched
targeted treatment with a median PFS of 204 days $(95\%$ CI
99 - N.A.), compared with 117 days $(95\%$ CI 106 - 143;
P=0.011) in all other patients. The respective molecular
targets were shown to be predictive for matched treatment
response and not prognostic surrogates for improved outcome.
Hereditary cancer predisposition syndromes were identified
in $7.5\%$ of patients, half of which were newly identified
through the study. Integrated molecular analyses resulted in
a change or refinement of diagnoses in $8.2\%$ of cases.},
cin = {B062 / HD01 / B310 / B300 / W190 / B060 / C060 / B360},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B310-20160331 / I:(DE-He78)B300-20160331 /
I:(DE-He78)W190-20160331 / I:(DE-He78)B060-20160331 /
I:(DE-He78)C060-20160331 / I:(DE-He78)B360-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34373263},
doi = {10.1158/2159-8290.CD-21-0094},
url = {https://inrepo02.dkfz.de/record/170170},
}